Sanofi and Regeneron Report Phase 2 Results for Lipid Drug
Sanofi and Regeneron Pharmaceuticals, Inc. announced that data from two Phase 2 trials with SAR236553 / REGN727 , an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 ( proprotein convertasesubtilisin / kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
Garlic is Great for Keeping Cholesterol Low
Sometimes it seems like no matter what you do, what lifestyle or diet changes you make, your cholesterol won't drop below 200. It turns out that all that might be missing from your diet is a little (or a lot) more garlic.
How Reliable a Link?
Though men who have vascular erectile dysfunction appear to be at a higher risk of developing cardiovascular disease, that doesn't mean ED alone should be considered a risk factor.
The Other Heart Benefit of Cholesterol Drugs
Cholesterol-lowering statin drugs may have an added benefit. They also appear to break down plaque in arteries, a major contributor to blood vessel blockages that can lead to a heart attack or stroke. Now, doctors know why.
Reverse Artery Plaque With Medications
Large doses of common cholesterol-lowering medications appear to reverse coronary artery disease by reducing the amount of plaque in clogged arteries.
There are many ways to keep your heart healthy. Is sex one of them and is sex even considered exercise? As people get older sex might seem like it’s too strenuous for the heart, but is it?
Type of Heart Disease Linked to Dementia
Dementia can be brought on by a number of risk factors. One of the most surprising that has recently been linked to the cognitive impairment, however, is a type of heart condition involving restricted arteries.
FDA Approves Drug for Acute Coronary Syndromes
The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta ( ticagrelor ) to reduce cardiovascular death and heart attack in patients with acute coronary syndromes (ACS).
(UPDATE 12/15) FDA Announces New Safety Recommendations For High-Dose Simvastatin
The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy , particularly during the first 12 months of use.
Their Hearts Will Go On
Mammalian newborn hearts can heal themselves completely, according to new research from the University of Texas Southwestern Medical Center.